Coherus Biosciences Could Be First-To-Market With A Neulasta Biosimilar

By: via Benzinga
Barclays maintained its Overweight rating on Coherus Biosciences Inc (NASDAQ: CHRS) saying there is an increased likelihood of CHRS ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.